Table 2.

Observed and estimated means, standard deviations, ESs (Cohen's d) for outcome measures.

	Observed means			ESs		Treatment vs. control ESs
	Pre	Post	Follow-up (3 months from week 1)	Pre to post	Pre to follow-up	Pre to post
PHQ-9
Treatment	11.95 (6.03)	7.63 (6.05)	6.73 (3.55)	0.72*	1.30*	0.78*
Control	12.78 (6.76)	11.84 (6.30)	NA	0.14	NA	NA
Control (cross-over)	11.84 (6.30)	7.83 (7.27)	6.83 (7.42)	0.59	0.73	NA
Treatment response	12.20 (5.66)	7.71 (6.47)	NA	0.74*	0.95*	0.51
Control response	10.62 (6.33)	9.97 (5.94)	NA	0.11	NA	NA
GAD-7
Treatment	8.50 (5.20)	5.31 (4.53)	4.27 (4.05)	0.65	0.91*	0.27
Control Control (cross-over)	11.47 (6.74) 10.53 (5.76)	10.53 (5.76) 5.83 (5.02)	NA 5.78 (4.47)	0.15 0.87*	NA 1.05*	NA NA
Treatment response Control response	9.44 (5.49) 8.56 (6.36)	5.54 (4.66) 8.23 (5.97)	NA NA	0.77* 0.05	0.97* NA	0.33 NA
WSAS
Treatment	15.32 (10.20)	9.31 (8.75)	9.00 (8.81)	0.63	0.66	0.36
Control Control (cross-over)	17.37 (8.91) 17.15 (10.26)	17.15 (10.26) 13.42 (10.24)	NA 12.38 (11.78)	0.02 0.37	NA 0.54	NA NA
Treatment Response Control Response	16.17 (10.14) 13.69 (9.31)	11.07 (9.46) 14.17 (10.40)	NANA	0.52 −0.05	0.59 NA	0.23 NA
K10
Treatment	23.91 (8.04)	19.44 (8.86)	18.27 (6.48)	0.53	0.77*	0.66
Control Control (cross-over)	27.37 (9.96) 25.68 (10.03)	25.68 (10.03) 20.80 (11.24)	NA16.80 (11.22)	0.17 0.46*	NA0.73*	NA NA
Treatment Response Control Response	24.73 (8.95) 24.15 (10.03)	20.10 (9.93) 23.96 (9.42)	NA NA	0.49* 0.02	0.74* NA	0.30 NA

Standard deviations are shown in parentheses. Pre, Pre-treatment; Post, Post-treatment; Follow-up, Three-month follow-up; PHQ-9, Patient Health Questionnaire 9-item; GAD-7, Generalised Anxiety Disorder 7-item.

^*indicates statistically significant results.